Light Chain Bioscience now focuses on leveraging the unique features of its bispecific antibody format”, said Erich Hunziker, Chairman of Light Chain Bioscience. Bispecific antibodies represent ...

Bispecific antibodies (bsAbs) are designed to recognise ... Solving the ‘chain-association issue’ The archetypal asymmetric format of bsAbs requires the expression of four unique chains.

Bispecific antibodies, which bind simultaneously to two different antigens, can attack tumors via novel mechanisms of action that cannot be evoked with combinations of conventional monoclonal ...

improving the half-life and efficacy of ADCs through strategies like the use of albumin-binding domains or small-format ...

ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at 18.30 EET Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies Orion Corporation and Alligator Bioscience AB ...

Transaction valued at €3.5 millionThe partners have enjoyed a successful discovery collaboration since 2021LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announ ...

Generates high-purity antibodies in any format (scFv, VHH, Fab, etc.) at affordable prices. Bispecific Antibody Production Service: Produces recombinant bsAbs in various formats.

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer ...

UK biotech company Kymab is to collaborate with China’s EpimAb Biotherapeutics to develop bispecific antibodies in the immuno-oncology field. Kymab has developed a next-generation antibody ...

Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and ...

LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announced that the Company has entered into an agreement under which Orion Corporation has settled all future ...